Roflumilast
arcutis biotherapeutics,Astrazeneca
['roflumilast', 'derm']
roflumilast 0.15% once-daily was found to be effective at improving #atopicdermatitis across multiple efficacy endpoints and produced favorable safety &amp; tolerability. check out the data here: #aad23 #roflumilast #aad2023
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.